Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs – PRNewswire



Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs  PRNewswire

LEXINGTON, Mass., Feb. 12, 2019 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM) has been awarded five new patents that expand the intellectual property …



Source link




Leave a Reply

Your email address will not be published. Required fields are marked *